ABSTRACT
INTRODUCTION

Endoscopic variceal ligation (EVL)
is an accepted treatment for esophageal variceal bleeding in patients with cirrhosis (1) (2) (3) (4) . Generally, patients who receive endoscopy, particularly for therapeutic purposes, are sedated to improve their procedural tolerability (5-7). Midazolam (MDZ) is one of the most commonly used sedative drugs with a short induction and recovery time (8) (9) (10) . Moreover, the actions of MDZ can be antagonized quickly by the antidote, flumazenil in case of adverse events (AEs). The mechanism of MDZ is mediated via a gamma-aminobutyric acid neurotransmitter system in the brain, which is reportedly associated with the development of hepatic encephalopathy (HE) (11) (12) (13) . Further, other AEs related to MDZ may occur more frequently in patients with cirrhosis due to the altered metabolism. However, data are limited regarding the sedation of patients with liver cirrhosis, particularly during EVL that needs proper sedation for a successful outcome. The safety and effectiveness of MDZ in patients with cirrhosis undergoing EVL were evaluated in the present study.
MATERIALS AND METHODS
Study population
The medical records of patients with cirrhosis who underwent EVL between October 2010 and December 2016 were reviewed retrospectively. Exclusion criteria comprised chronic use of benzodiazepines, overt HE, and state of cardiopulmonary dysfunction defined as follows: hypotension (systolic blood pressure<90 mm Hg and/or diastolic blood pressure<50 mm Hg), bradycardia (heart rate<55 beats per minute), and desaturation (<90% on pulse oximetry). Patients undergoing endoscopic screening were not included. Patients were divided into two groups according to the use of MDZ (MDZ group and non-MDZ group). In the MDZ group, a dose of 0.05 mg/kg was administered initially with additional doses of 1 mg every 3 min as necessary until the maximum dose of 0.075 mg/kg or 7.5 mg. In the non-MDZ group, patients received EVL without sedation. The level of sedation was regulated to facilitate EVL with minimal discomfort to the patients without cardiorespiratory compromise.
Each patient was monitored using pulse oximetry and noninvasive blood pressure measurement. Furthermore, the respiratory rate and level were monitored every 10 min during the procedure and in the recovery room. The level of consciousness was recorded on a 5-point Observer's Assessment of Awareness/Sedation Scale, wherein 1=awake, 2=somnolent/drowsy, 3=responsive to loud or repeated verbal stimuli, 4=responsive to physical/painful stimuli, and 5=no response to physical/painful stimuli (14) .
Oxygen was supplied through a nasal cannula throughout the procedure and in the recovery room as needed. All the patients were hospitalized during the procedure and until full recovery. Patients were monitored at the intensive care unit if necessary. The Institutional Review Board gave approval for the present study. Written informed consents for voluntary participation were obtained from all the patients (DUIH-IRB 2013-101).
Endoscopic procedures
EVL was performed using a standard technique. In brief, EVL was started from the gastroesophageal junction and advanced proximally for patients who were undergoing elective therapy with 2 to 6 bands. Emergency EVL was performed for patients who had active esophageal bleeding within 12 h, using 1 or 2 bands at the bleeding point. All endoscopic procedures were performed with gastrointestinal videoscopes (GIF-H260 and EVIS-260 A/B; Olympus, Tokyo, Japan). Procedure time was de- Table 2 . Baseline characteristics fined as the time from the passage of the endoscope through the cricopharyngeus muscle until removal of the endoscope. Esophageal varices were graded using the Paquet grading systems, wherein grade 0=no varices; grade 1=disappearing with insufflation; grade 2=larger, clearly visible, usually straight varices, not disappearing with insufflation; grade 3=more prominent varices, locally coil-shaped and partly occupying the lumen; and grade 4=tortuous, sometimes grape-like varices occupying the esophageal lumen (15) .
Outcomes of interest and statistical analysis
The primary outcome of interest was treatment success. The secondary outcomes were procedure time, AEs, and mortality within 30 days. Treatment success was defined as successful ligation of the varices confirmed by follow-up endoscopy performed 48 h after the procedure. AEs were defined as the occurrence of any undesired events, and their relationship with MDZ could not be excluded.
HE was defined and graded according to the West Haven criteria, wherein grade 1=trivial lack of awareness, shortened attention span, impaired performance of addition, and euphoria or anxiety; grade 2=lethargy or apathy, minimal disorientation for time or place, subtle personality change, and inappropriate behavior; grade 3=somnolence to semi-stupor but responsive to verbal stimuli, confusion, and gross disorientation; and grade 4=coma (16) . Hypoxemia was defined as oxygen saturation<90% and patient unresponsive for 15 s to jaw extension maneuver, verbal stimulus, or an increase in oxygen supplementation. Bradycardia was defined as a 25% decrease in initial heart rate or heart rate <55 beats per minute.
Risk factors and comorbidities affecting the development of AEs and HE were also evaluated. (Table 3) . For HE, an ECOG score of ≥2 (p=0.01), high serum creatinine level (p=0.02), and the use of MDZ (p<0.01) were significant factors in multivariate analysis (Table 4) . Overall, overt HE developed in 10 (3.1%) out of the 320 patients after EVL, and all of them recovered within 4 days.
In subgroup analyses with patients who were in grade C based on the Child-Pugh classification (Table 5 ) and actively bleeding (Table 6) , an ECOG score of ≥2 (p=0.04) and old age (p=0.01) were associated with overall AEs, respectively. Table 5 . Subgroup analyses of patients in grade C based on the Child-Pugh classification for the development of overall adverse events*
DISCUSSION
The results of 151 patients with cirrhosis who received MDZ sedation during EVL and 169 patients who did not receive sedation were compared in the present study. We found that desaturation, bradycardia, and HE were more common in the MDZ group than in the non-MDZ group during EVL in patients with cirrhosis. Development of overall AEs was associated with high ECOG score and the use of MDZ. AEs in HE developed in patients with high ECOG score, elevated serum creatinine level, and the use of MDZ.
In general, sedation is widely used for safe and successful procedure during endoscopic procedures (6). However, there are no specific guidelines for patients with cirrhosis although they frequently undergo endoscopy for screening and treatment of complications related to portal hypertension (18) . Cooperation from patients is crucial for successful EVL, particularly for bleeding varices. Endoscopists frequently face a dilemma in this critical situation, particularly for patients who show uncontrollable agitation and aggressive behaviors. However, because concurrent hypovolemia is usual, there may be hesitation in using sedation for fear of cardiovascular AEs. In addition, even after a successful EVL, development of HE is a concern.
MDZ is widely used owing to its short half-life as well as anxiolytic and amnestic effects in a population with no cirrhosis (19) . Following hepatic clearance, MDZ is metabolized by hydroxylation and conjugation with glucuronic acid (20) . Decreased protein binding, intrinsic clearance, and metabolism combined with an increased volume of distribution contribute to a markedly prolonged half-life in patients with cirrhosis (20) (21) (22) .
Conflicting results regarding the safety of MDZ in patients with cirrhosis were found. A few studies reported that subclinical HE is worse after MDZ administration (23) (24) (25) (26) . In contrast, other studies reported that MDZ may be used safely in patients with cirrhosis (18, 27, 28) . Table 6 . Subgroup analyses of patients with active bleeding for the development of overall adverse events* However, the correlation between MDZ and overt HE cannot be established because patients were discharged directly from an endoscopy unit or a recovery room and post-procedural monitoring was confined to 2 h in all the relevant studies. In our study, observation for an adequate period of time was possible because each patient was hospitalized until full recovery. Moreover, it could not be assessed whether risks of sedating patients with cirrhosis with MDZ outweighed the benefits of adequate procedure because none of the above included patients with cirrhosis with bleeding varices. Although Correia et al. included cases of EVL, the number is small (31 in the MDZ group) and does not include bleeding varices (18) . In addition, our study population was homogenous because patients undergoing endoscopic screening were excluded. To the best of our knowledge, this is the first study that included patients with cirrhosis who received emergency procedures for bleeding varices.
Recently, sedation with propofol in patients with liver cirrhosis was reported (18, 25, 29, 30) . Rapid recovery and improved patient comfort might be advantages associated with the use of propofol in patients with cirrhosis. However, propofol induces deep sedation without any antidotes and may increase the frequency of cardiovascular AEs compared with traditional agents (31) . Furthermore, most of the data were obtained from less sick patients based on the American Society of Anesthesiologists classification≤3 or Child-Pugh classification A or B, and the safety of propofol in more serious patients was still a matter of concern.
The present study has several limitations. First, the patients from the non-MDZ group showed greater degree of severity in terms of previous history of HE, Child-Pugh classification, active bleeding, and variceal grade than those from the MDZ group. Nevertheless, AEs were more frequent in the MDZ group than in the non-MDZ group, suggesting a risk associated with the use of MDZ in patients with cirrhosis. Second, subclinical HE could not be evaluated because many of the patients received EVL in the emergency setting. Finally, the scales of patient discomfort could not be assessed in the present study.
In conclusion, extreme caution should be taken when sedating patients with cirrhosis receiving EVL because AEs are associated with the use of MDZ.
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